Adaptive radiation aims to outsmart aggressive brain tumors

NCT ID NCT05720078

First seen Jul 01, 2026 · Last updated Jul 01, 2026

Summary

This study tests whether a personalized, two-phase radiation therapy approach can better control glioblastoma, an aggressive brain cancer. The treatment adapts the radiation plan based on tumor changes during therapy, potentially targeting the tumor more precisely while sparing healthy tissue. Researchers will compare local control, survival, and side effects between this adaptive method and standard radiation in 70 adults with newly diagnosed glioblastoma.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

adaptive radiation therapy

What this could lead to

If successful, this approach could improve local tumor control and reduce side effects for people with glioblastoma.

What could go wrong

This is a relatively small, early-phase study, so results may not apply broadly. The adaptive technique is complex and may not improve outcomes over standard care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME, ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adult glioblastoma glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, M4N3M5, Canada